Listen: Can California Lower the Price of Insulin?

California Healthline senior correspondent Angela Hart appeared on KCRW’s “Press Play With Madeleine Brand” and KJZZ, a public radio station in Phoenix, this month to discuss California’s plan to reduce the cost of some prescription medications — starting with insulin — by diving into the generic drug market.

California lawmakers set aside $100 million in the recently adopted 2022-23 state budget to help launch the CalRx drug label, and the state could start producing generic insulin within the next few years, according to Gov. Gavin Newsom’s administration. The goal is to make the drug available to millions of Californians via pharmacies, retail stores, and mail order, administration officials say.

Initially, the state would contract with a drug manufacturer to make and distribute the drug, which currently costs about $300 to $400 per vial without insurance. Many questions remain unanswered, such as how cheaply insulin could be produced and what patients would pay.

“In terms of the cost, there are some companies that are talking about producing this for about … $30 a vial,” Hart told KCRW.

You can read Hart’s coverage of the plan here and here.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

We encourage organizations to republish our content, free of charge. Here’s what we ask:

You must credit us as the original publisher, with a hyperlink to our khn.org site. If possible, please include the original author(s) and “Kaiser Health News” in the byline. Please preserve the hyperlinks in the story.

It’s important to note, not everything on khn.org is available for republishing. If a story is labeled “All Rights Reserved,” we cannot grant permission to republish that item.

Have questions? Let us know at [email protected]

Comments are closed.